NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to begin a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo (DRC). The company submitted an application to the local regulatory agency, with financing already secured to support the study. This development comes amid an ongoing Ebola outbreak caused by the Bundibugyo strain, for which no approved treatment or vaccine currently exists.
NV-387 is, to the company's knowledge, the only orally administered Ebola treatment candidate currently under consideration for clinical testing. NanoViricides believes its broad-spectrum antiviral mechanism could offer significant advantages over infusion-based therapies, particularly in resource-limited outbreak settings where intravenous administration is challenging. The company stated that sufficient quantities of the drug are already in the DRC to support the planned study, pending regulatory approval.
The significance of this announcement lies in the potential to address a critical gap in Ebola treatment. The Bundibugyo strain has caused sporadic outbreaks with high mortality, and the lack of specific countermeasures hampers containment efforts. An oral antiviral like NV-387 could simplify deployment and reduce the burden on healthcare infrastructure during outbreaks. If successful, this trial could pave the way for a novel therapeutic option that is easier to administer and stockpile compared to injectable drugs.
NanoViricides' platform technology is based on nanomedicine, with NV-387 designed as a broad-spectrum antiviral. The company is also developing NV-387 for other viral infections, including RSV, COVID-19, and influenza. The current focus on Ebola underscores the versatility of the platform and the company's commitment to addressing neglected tropical diseases. The outcome of the regulatory decision and subsequent trial will be closely watched by global health authorities and investors alike.
For more details, the full press release is available at https://ibn.fm/t1kLC. Additional updates on NanoViricides can be found in the company's newsroom at https://ibn.fm/NNVC.
